flow trial semaglutide kidney outcomes nejm 2024 hazard ratio results 0.76 and Survival Benefits of in Diabetes With Chronic Kidney Disease: Cardiovascular Subgroup Analyses Semaglutide in Patients with Heart – FLOW- the flow trial semaglutide kidney outcomes

For years, those living with type 2 diabetes, obesity, and heart disease have searched for effective diabetes medications to manage their health better

Iron deficiency anemias can be regenerative or non-regenerative (Harvey et al 1982, Weiser and OGrady 1983)

While microdosing GLP-1s may be beneficial for a variety of reasons for certain individuals, the growing interest in microdosing GLP-1s can at least in part be tied to the significant metabolic shifts women experience during perimenopause and menopause

It works by mimicking a hormone that targets brain areas regulating appetite and food intake, helping to control hunger and create a feeling of fullness

March 3 -7, 2025, is Obesity Care Week